Lynwood Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Lynwood Capital Management’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-51,400	Closed	-$519K	–	166
2022 Q4	$519K	Hold	51,400	–	–	0.62%	54
2022 Q3	$509K	Hold	51,400	–	–	0.56%	61
2022 Q2	$504K	Hold	51,400	–	–	0.56%	58
2022 Q1	$504K	Sell	51,400 -1	-0%	-$10	0.54%	57
2021 Q4	$515K	Buy	+51,401	New	+$500K	0.49%	57

Lynwood Capital Management's IBER Position: Q1 2023 in Review

Lynwood Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 51,400 shares — an estimated $519K sold.

Lynwood Capital Management first reported a position in IBER in Q4 2021 and held it in 5 quarters. The position peaked at $519K in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Lynwood Capital Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Lynwood Capital Management sold 51,400 Ibere Pharmaceuticals shares in Q1 2023, an estimated $519K.
Lynwood Capital Management first reported a position in Ibere Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Lynwood Capital Management's Ibere Pharmaceuticals position peaked at $519K in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Lynwood Capital Management's 13F filing for Q1 2023, filed 12 May 2023.